Videos

Janet E McDonagh, MD, FRCP explains the importance of obtaining both the patient and parent perspective in pediatric rheumatology.

Zachary S Wallace, MD, explains his approach to diagnosing and managing IgG4-related disease and some of the clinical trials that are on the horizon.

Leonard Calabrese, DO, explains the history of interferon history in rheumatology, immunology for the rheumatologist, and COVID-19 immunology regarding autoimmune and inflammatory manifestations.

Pri-Med West presenter, Dr. Peng Thim Fan asks the questions that many rheumatologists have likely been contemplating now that disease treatment is so successful.

While some physicians might initially assume that oral medications like upadacitinib aren't as effective as an injection, but Dr. Fan explains that's not the case.

Janet E McDonagh, MD, FRCP, discusses the study “The Role of Age in Delays to Rheumatological Care in Juvenile Idiopathic Arthritis.”

Expert rheumatologist Dr. Peng Thim Fan explains that the effects of COVID-19 are still being examined.

ANCA-associated vasculitis may present like sinusitis, but it typically affects multiple organ systems.

Jeffrey Stark, MD, discusses the latest bimekizumab and certolizumab pegol data presented at the 2022 American Academy of Dermatology annual meeting.

Dr. Warrington discusses the details of glucocorticoids and how avacopan can help with the effective treatment of ANCA-associated vasculitis.

Shanthini Kasturi, MD, MS, discusses the importance of patient-reported outcome measures to optimize the care of patients with systemic lupus erythematosus.

Joyce C. Chang MD, MSCE, discusses the racial disparities in renal outcomes for hospitalized children with systemic lupus erythematosus.

Because vasculitis can manifest in various ways, Matthew Koster, MD, talks about identifying Granulomatosis with polyangiitis and other forms of the disease.

Tanaz Kermani, MD, MS, talks about the current state of vasculitis care and the latest research in the field.

Dr. Kenneth J. Warrington led the panel in discussing various topics in rheumatology.

Jeff Peterson, MD, explains the importance of the recent FDA announcement granting priority review of the Supplemental Biologics License Application for concomitant use of pegloticase injection (KRYSTEXXA) plus methotrexate for patients with uncontrolled gout.

Advice to rheumatologists in terms of staying up to date on newer treatment options entering the market for lupus.

Novel therapies in the pipeline that demonstrate potential advantages when used as treatment for systemic lupus erythematosus and lupus nephritis.

John Tesser, MD, closes the discussion with unmet needs in the PsA treatment landscape, as well as what he hopes to see in the future.

Expert panelists share tips for boosting patient compliance among patients with psoriatic arthritis.

Three colleagues share insights into their evolving approaches regarding the management of patients with psoriatic arthritis who test positive for COVID-19.

Expert John Sergent shares insight on his best practices treating patients with autoimmune diseases.

Recommendations for monitoring patients on novel therapies used to manage lupus nephritis and making decisions to taper or stop treatment.

The rationale for treating lupus nephritis with novel therapies such as belimumab and voclosporin.

John Tesser, MD; Nehad Soloman, MD; and Jennifer Simpson, DNP, emphasize the important of vaccination against COVID-19 for patients with psoriatic arthritis.

A panel of experts and colleagues recall the indicators and steps that need to be taken when changing PsA therapies.

The rationale for using a newer monoclonal antibody therapy, anifrolumab, to manage patients with systemic lupus erythematosus.

Indications for belimumab, a monoclonal antibody, as therapy for patients with systemic lupus erythematosus.

Three experts discuss measurement of outcomes for psoriatic arthritis management and what a “successful” treatment looks like.